Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Effectiveness and safety profile of pola-based regimen in DLBCL Patients with high-risk factors in real world: A retrospective study in China

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMiaomiao Liu

Discussion

Loading...

Member takes

Overview

Retrospective analysis found pola-based regimen led to complete response in high-risk DLBCL patients, suggesting manageable toxicity.

Key Points

  • Pola-based regimens demonstrated a complete response rate of 50% in high-risk DLBCL patients, with manageable safety profiles.
  • Adverse events included anemia and low white blood cell counts, with 37.5% of patients experiencing grade 3–4 toxicity.
  • Retrospective study conducted at Changhai Hospital evaluated 30 patients treated with pola-based regimens.
  • Results support the efficacy of pola-based therapy in high-risk populations, highlighting the need for further follow-up data.

Cite This Study

Miaomiao Liu (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2aehttps://doi.org/10.1182/blood-2025-7222
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of pola-based therapy in molecularly defined high-risk DLBCL: A retrospective analysis of real-world data2025
  2. 2The efficacy and safety of polatuzumab vedotin-based regimens in the treatment of diffuse large B-cell lymphoma: A retrospective real-world study2025
  3. 3Efficacy and safety of polatuzumab vedotin–based regimens in newly diagnosed diffuse large B-cell lymphoma: A single-center retrospective study2025
  4. 4Polatuzumab-vedotin in large diffuse B-cell lymphoma: A multicenter observational study from Latin America (2020–2024)2025
  5. 5A retrospective Study of pola-R-CHP regimen in treatment-naive patients with diffuse large B-cell lymphoma from northeast China2025